NASDAQ:BIAF bioAffinity Technologies Q3 2026 Earnings Date & Estimates $2.38 +0.12 (+5.35%) As of 03:10 PM Eastern This is a fair market value price provided by Massive. Learn more. bioAffinity Technologies is estimated to report Q3 2026 earnings on Wednesday, November 18, 2026, before market opens. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 18, 2026TimeBefore Market Opens Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from bioAffinity Technologies in Q3 2026bioAffinity Technologies is expected to post earnings of -$31.50 per share on revenue of $1.91 million. In the same quarter a year earlier bioAffinity Technologies reported -$40.50 per share on revenue of $1.45 million. bioAffinity Technologies last reported on November 6, 2026, posting -$3.94 per share and beating the -$31.50 consensus estimate. bioAffinity Technologies has beaten the consensus EPS estimate in 4 of its last 8 quarters.Consensus EstimatesConsensus EPS-$31.50Expected Revenue$1.91 millionPrior-Year EPS-$40.50Prior-Year Revenue$1.45 millionExpected Revenue Growth+31.7%Recent Track RecordLast ReportedQ3 2026Last Quarter EPS-$3.94 (Beat by +$27.56)Last Quarter Revenue$1.07 millionEPS Beat Rate4 of last 8 quartersPrepare for the Q3 2026 CallPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Q3 2026 Earnings ReportQ2 2026 Earnings ReportQ1 2026 Earnings Report Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) bioAffinity Technologies Q3 2026 Earnings FAQ When does bioAffinity Technologies report Q3 2026 earnings? bioAffinity Technologies (NASDAQ:BIAF) is estimated to report Q3 2026 earnings on Wednesday, November 18, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is bioAffinity Technologies' Q3 2026 earnings call? bioAffinity Technologies' Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 7:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for bioAffinity Technologies? Analysts expect bioAffinity Technologies to post earnings of -$31.50 per share for Q3 2026. How much revenue is bioAffinity Technologies expected to report? The consensus revenue estimate for bioAffinity Technologies is $1.91 million for Q3 2026. bioAffinity Technologies Earnings HeadlinesbioAffinity Technologies Reports Third Quarter 2026 Results and Continued Momentum in CyPath® Lung CommercializationNovember 6, 2026 | businesswire.combioAffinity Technologies Highlights Importance of Link Between Early Lung Cancer Detection and Curative Treatment During National Lung Cancer Awareness MonthOctober 29, 2026 | finance.yahoo.comI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.November 10 at 1:00 AM | Behind the Markets (Ad)bioAffinity highlights CyPath Lung at CHEST 2026October 15, 2026 | tipranks.combioAffinity to Present New Sputum-Based Lung Biomarker DataOctober 13, 2026 | tipranks.comBioAffinity Technologies Closes $4 Million Direct Offering, Private PlacementOctober 9, 2026 | finance.yahoo.comSee More bioAffinity Technologies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like bioAffinity Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on bioAffinity Technologies and other key companies, straight to your email. Email Address About bioAffinity TechnologiesbioAffinity Technologies (NASDAQ:BIAF) is a biotechnology company focused on developing diagnostic and therapeutic products for cancer and other serious diseases. The company’s platform uses porphyrin-based compounds designed to selectively identify or target abnormal cells, with the goal of supporting earlier disease detection and more precise treatment. Its lead diagnostic product, CyPath Lung, is an investigational, noninvasive urine test intended to aid in the detection of lung cancer. The test uses an inhaled porphyrin compound that can bind to cancer cells in the lungs; the resulting material is collected in urine and analyzed using laboratory methods. CyPath Lung is designed to complement existing lung-cancer screening and diagnostic procedures, rather than replace them. bioAffinity is also developing therapeutic applications of its technology for cancer and other diseases. The company is based in Albuquerque, New Mexico, and conducts its research, product development and clinical activities in the United States. Its products remain subject to applicable regulatory review and authorization before they can be broadly marketed.View bioAffinity Technologies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
